EZH2 and prostate carcinoma: Analysis of transcriptional profiles from a panel of prostate cancers and normal prostate tissue confirms this pattern of expression and reveals that 92% of metastatic samples express EZH2 at levels ≥3 SD higher than those observed in normal prostate tissue (Fig 1A and S1 Data; [16]).